再生元联合创始人兼首席科学官乔治·扬科普洛斯说，临床研究表明，使用GLP-1药物来减肥的患者肌肉流失速度远远快于通过节食或运动减肥的人，这可能会使他们面临健康问题。①American pharmaceutical company Regeneron stated that current GLP-1 weight-loss drugs can lead to rapid muscle loss, and the company is developing weight-loss drugs that can overcome this defect; ②Regeneron warned that if the issue of muscle loss cannot be resolved, GLP-1 weight-loss drugs may do more harm than good.
On October 7th, Caishang News (Editor Xia Junxiong) While novo-nordisk and eli lilly, two giants, dominate the market for GLP-1 weight-loss drugs, some pharmaceutical companies are trying to outperform them.
American pharmaceutical company Regeneron stated that current GLP-1 weight-loss drugs can lead to rapid muscle loss, and the company is developing weight-loss drugs that can overcome this defect. Regeneron warned that if the issue of muscle loss cannot be resolved, GLP-1 weight-loss drugs may do more harm than good.
Co-founder and Chief Scientific Officer of Regeneron, George Yancopoulos, said that clinical studies have shown that patients using GLP-1 drugs for weight loss experience much faster muscle loss than those losing weight through diet or exercise, which may pose health risks for them.
Yancopoulos cited a study published this year in the Journal of the American Medical Association, which showed that one-fifth of patients stop using GLP-1 weight-loss drugs within a year, indicating that they may rebound to their original weight with less muscle and higher body fat percentage, which is undoubtedly adding insult to injury.
Yancopoulos stated that the use of GLP-1 weight-loss drugs should be highly scrutinized, as they may gradually change the ratio of fat to muscle, which may ultimately do more harm than good.
Clinical data shows that patients using eli lilly and novo-nordisk drugs for weight loss have achieved significant effectiveness, but have lost a large amount of muscle. Among them, patients using eli lilly drugs had 25% of weight loss coming from lean mass (including muscle), while with novo-nordisk weight-loss drugs, this figure reached 40%.
The United States Food and Drug Administration (FDA) recommends that patients using GLP-1 drugs for weight loss should combine them with diet and exercise.
Renewgen is developing a pharmaceutical called trevogrumab, and the initial clinical data of the Phase II trial of this drug is expected to be released in mid-next year. The company
Renewgen is also considering whether to advance the clinical trial stage of its GLP-1 drugs, which have already been tested on mice. Despite Yang Coplos's concerns about the drug, he stated that Renewgen is considering becoming a participant in GLP-1 drugs.
Yang Coplos said: "I am not sure if GLP is the real ultimate answer, as they may bring significant long-term issues."